Track topics on Twitter Track topics that are important to you
VANCOUVER, BC--(Marketwired - June 02, 2015) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce the appointment of Dr. Randal Chase to its Board of Directors. Dr. Chase currently serves as Chairman of MediMabs, a privately held company, and is a member of the Board of Geovax Labs, Inc., a vaccine company trading on the OTCQX.
Dr. Chase began his career at Bristol Meyers and Glaxo Canada Inc., where he held the positions of Director and Senior Vice President, respectively. He is a former President of several companies, including Quadra Logic Technologies, Inc., North American Vaccine and Aventis Pasteur Canada. As well, Dr. Chase has served as President and Chief Executive Officer of ImmunoVaccine Technologies Inc. from 2006 to 2011. From 2005 to 2006, he was Chairman of the Board of Directors of Molecular Templates Inc. From 2001 to 2004, Dr. Chase was President of Shire Biologics Inc and from May 2001 to August 2002, he served as Senior Vice-President, Vaccines Operations of Biochem Pharma Inc. Among his numerous appointments, Dr. Chase has been a member of the board of Biotech Canada, and has served as a Director of Bioject Medical Technologies, Inc. (NASDAQ), Acambis PLC (London Stock Exchange, NASDAQ), and of Conjuchem Inc. and of Conjuchem Biotechnologies Inc. (TSX). Most recently, Dr. Chase was Chairman of the Board and Director of Medicago, a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide.
Dr. Chase, who holds a B.Sc. degree (biochemistry) from Bishop's University, obtained a PhD from the University of British Columbia in 1974, and subsequently completed a postdoctoral fellowship at the McArdle Cancer Institute of the University of Wisconsin.
Allen (Alexander) Krantz, President of APC commented that "We have been fortunate in having the benefit of Dr. Chase's guidance over the past few years as a member of our Corporate Advisory Board. We are delighted that Dr. Chase will now be joining our Board of Directors. Randal has had a remarkable record of success over four decades of high level leadership positions in both private and public entities. His impressive technology background, his broad life science business experience, and proven leadership skills will certainly be an asset to the Company and provide a strong complement to our executive team."
APC has been applying its Foundation Trinity™ Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent, that can also, in turn, be combined with additional agents to enhance therapies.
To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface -- both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.FOR FURTHER INFORMATION PLEASE CONTACT: Advanced Proteome Therapeutics Corporation Alexander (Allen) Krantz President and Chief Executive Officer Tel: (617) 638-0340 Scott Young Investor Relations Tel: (705) 888-2756NEXT ARTICLE